Journal of Immunology Research

Immunotherapy for Multiple Myeloma


Publishing date
04 May 2012
Status
Published
Submission deadline
04 Nov 2011

1Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

2Department of Hematology, University of Nantes, Nantes, France

3Department of Hematology and Stem Cell Transplantation, The Chaim Sheba Medical Center, Tel Hashomer, Israel

4Department of Lymphoma/Myeloma and Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA


Immunotherapy for Multiple Myeloma

Description

Multiple myeloma is a malignancy which accounts for 14% of all hematological malignancies and for nearly 2% of all cancers. Despite progress in understanding of the disease biology and improvement therapeutic options in the recent years, multiple myeloma remains an incurable disease. A long-lasting remission after donor lymphocyte infusion in patients with relapse disease after allogeneic stem cell transplantation, the cytotoxic effect of new immunomodulating agents such as thalidomide and lenalidomide as well as immunotherapy in vitro models strongly supported the efficacy of immunotherapy-based therapy. Further improvement in understanding of immunological interactions between myeloma cells and microenvironment as well as the development of vaccination strategies and cell therapy approaches will certainly improve the therapeutic armamentarium in the treatment of multiple myeloma. We invite the authors to submit original research and review articles which help to design new immunotherapy-based therapeutic options in treatment of multiple myeloma. Potential topics include, but are not limited to:

  • Development and testing of immunotherapy in in vitro models mimicking multiple myeloma
  • Immunotherapy-based approaches targeting microenvironment and the neoplastic niche of multiple myeloma
  • Elucidating the role of the adoptive and innate immunsystem in controlling multiple myeloma
  • Identification of new myeloma-specific targets for immunotherapy
  • The role of genetically modified immunsystem to target multiple myeloma
  • Potential role of monoclonal and polyclonal antibodies in the treatment of multiple myeloma
  • Immunological-based therapies to target the neoplastic niche
  • Elucidating the role of vaccination strategies

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/jir/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:

Manuscript DueFriday, 4 January 2012
First Round of ReviewsFriday, 29 April 2012
Publication DateFriday, 29 July 2012

Lead Guest Editor

  • Nicolaus Kröger, Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

Guest Editors

  • Mohamad Mohty, Department of Hematology, University of Nantes, Nantes, France
  • Arnon Nagler, Department of Hematology and Stem Cell Transplantation, The Chaim Sheba Medical Center, Tel Hashomer, Israel
  • Qing Yi, Department of Lymphoma/Myeloma and Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Articles

  • Special Issue
  • - Volume 2012
  • - Article ID 797165
  • - Editorial

Immunotherapy for Multiple Myeloma

Nicolaus Kröger | Mohamad Mohty | ... | Qing Yi
  • Special Issue
  • - Volume 2012
  • - Article ID 652130
  • - Research Article

Impact of the NK Cell Receptor LIR-1 (ILT-2/CD85j/LILRB1) on Cytotoxicity against Multiple Myeloma

Silke Heidenreich | Christine zu Eulenburg | ... | Nicolaus Kröger
  • Special Issue
  • - Volume 2012
  • - Article ID 753407
  • - Review Article

Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions

Ivetta Danylesko | Katia Beider | ... | Arnon Nagler
  • Special Issue
  • - Volume 2012
  • - Article ID 820394
  • - Review Article

Immunogenic Targets for Specific Immunotherapy in Multiple Myeloma

Lu Zhang | Marlies Götz | ... | Jochen Greiner
  • Special Issue
  • - Volume 2012
  • - Article ID 196063
  • - Review Article

Targeting Multiple-Myeloma-Induced Immune Dysfunction to Improve Immunotherapy Outcomes

Sergio Rutella | Franco Locatelli
  • Special Issue
  • - Volume 2012
  • - Article ID 293479
  • - Review Article

The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma

Walter M. T. Braga | Djordje Atanackovic | Gisele W. B. Colleoni
  • Special Issue
  • - Volume 2012
  • - Article ID 397648
  • - Review Article

Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?

Thanh-Nhan Nguyen-Pham | Yoon-Kyung Lee | ... | Je-Jung Lee
  • Special Issue
  • - Volume 2012
  • - Article ID 134081
  • - Clinical Study

Longitudinal Analysis of Tetanus- and Influenza-Specific IgG Antibodies in Myeloma Patients

Sebastian Kobold | Tim Luetkens | ... | Djordje Atanackovic
  • Special Issue
  • - Volume 2012
  • - Article ID 257695
  • - Review Article

Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma Therapy

Fabricio de Carvalho | André L. Vettore | Gisele W. B. Colleoni
Journal of Immunology Research
 Journal metrics
Acceptance rate40%
Submission to final decision65 days
Acceptance to publication30 days
CiteScore3.330
Impact Factor3.404
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.